🔎 Trials Near Me

Acasă › Leucemie limfatică cronică › Maryland

Studii clinice pentru Leucemie limfatică cronică în Maryland

23 studii pentru Leucemie limfatică cronică caută participanți în Maryland.

Orașe în Maryland

Text oficial al studiului (în engleză)

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

  • National Institutes of Health Clinical Center, Bethesda
În curs de recrutareStudiu observațional
Vârste de la 18 la 110 · Toate sexele · Actualizat 2 oct. 2026 · NCT05724121

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Mercy Medical Center, Baltimore
  • Sinai Hospital of Baltimore, Baltimore
  • MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
  • și încă 10
În curs de recrutareStudiu observaționalVoluntari sănătoși bineveniți
Vârste de la 40 la 75 · Toate sexele · Actualizat 2 oct. 2026 · NCT05334069

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
  • Walter Reed National Military Medical Center, Bethesda
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 30 sept. 2026 · NCT04269902

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

  • GC2202 Study Site 111, Bethesda
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 30 sept. 2026 · NCT05645107

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  • The University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 28 sept. 2026 · NCT06943872

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  • American Oncology Partners of Maryland Pa, Bethesda
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Toate sexele · Actualizat 28 sept. 2026 · NCT05006716

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

  • American Oncology Partners of Maryland Pa, Bethesda
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 28 sept. 2026 · NCT06846671

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

  • National Institutes of Health Clinical Center, Bethesda
În curs de recrutareStudiu observațional
Vârste de la 18 la 110 · Toate sexele · Actualizat 28 sept. 2026 · NCT00923507

Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

  • National Institutes of Health Clinical Center, Bethesda
În curs de recrutareFaza 2
Vârste de la 18 la 85 · Toate sexele · Actualizat 24 sept. 2026 · NCT03986034

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

  • Center for Cancer and Blood Disorders ( Site 5439), Bethesda
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 24 sept. 2026 · NCT05947851

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

  • National Institutes of Health Clinical Center, Bethesda
În curs de recrutareStudiu observaționalVoluntari sănătoși bineveniți
Vârste de 18 ani și peste · Toate sexele · Actualizat 22 sept. 2026 · NCT01087333

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  • Johns Hopkins Asthma & Allergy Center, Baltimore
  • American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 21 sept. 2026 · NCT07648264

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

  • Maryland Oncology Hematology, Silver Spring
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 17 sept. 2026 · NCT07221500

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • University of Maryland, Baltimore
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 8 sept. 2026 · NCT03666000

Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib

  • National Institutes of Health Clinical Center, Bethesda
În curs de recrutareFaza 1 timpurie
Vârste de la 18 la 100 · Toate sexele · Actualizat 21 aug. 2026 · NCT07428707

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

  • American Oncology Partners of Maryland, PA, Bethesda
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 17 aug. 2026 · NCT05254743

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

  • The Center for Cancer and Blood Disorders-Bethesda, Bethesda
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 11 aug. 2026 · NCT07342478

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

  • National Institutes of Health Clinical Center, Bethesda
În curs de recrutareFaza 1/2
Vârste de la 18 la 120 · Toate sexele · Actualizat 16 iul. 2026 · NCT06364423

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  • National Institute of Health, Bethesda
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 2 iul. 2026 · NCT05131022

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  • American Oncology Partners, PA, Bethesda
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 19 mai 2026 · NCT06588478

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

  • Center for Cancer and Blood Disorders-American Oncology Partners of Maryland /ID# 266445, Bethesda
  • Maryland Oncology Hematology - Silver Spring /ID# 267557, Silver Spring
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 9 apr. 2026 · NCT06428019

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

  • National Institutes of Health Clinical Center, Bethesda
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 20 mar. 2026 · NCT04830137

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

  • University of Maryland Medical Center - Greenebaum Comprehensive Cancer Center, Baltimore
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 10 dec. 2025 · NCT05602363

Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.